Serum urate at trial entry and ALS progression in EMPOWER

References

• Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166:561–7.
   PubMed Web of Science ®Google Scholar
• de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson's disease. Ann Neurol. 2005;58:797–800.
   PubMed Web of Science ®Google Scholar
• Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson'sisease. Arch Neurol. 2009;66:1460–8.
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson's disease. Arch Neurol. 2008;65:716–23.
   PubMed Web of Science ®Google Scholar
• Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord. 2010;25:224–8.
   PubMed Web of Science ®Google Scholar
• Lee JE, Song SK, Sohn YH, Lee PH. Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord. 2011;26:1533–6.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285:95–9.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Guo X, Wei Q, Song W, Cao B, Huang R, et al. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metab Brain Dis. 2014;29:771–5.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in males with amyotrophic lateral sclerosis. J Neurol. 2012;259:1923–8.
   PubMed Web of Science ®Google Scholar
• Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population based study. JAMA Neurology. 2014;71:1134–42.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719–25.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51:1501–8.
   PubMed Web of Science ®Google Scholar
• O'Reilly EJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:205–11.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomized, double-blind, phase III trial. Lancet Neurol. 2013;12:1059–67.
   PubMed Web of Science ®Google Scholar
• Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18:1341–54.
   PubMed Web of Science ®Google Scholar
• Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162–8.
   PubMed Web of Science ®Google Scholar
• Mumford SL, Dasharathy SS, Pollack AZ, Perkins NJ, Mattison DR, Cole SR, et al. Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. Hum Reprod. 2013;28:1853–62.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011;258:238–43.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.
   PubMed Web of Science ®Google Scholar
• Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is baseline adjustmentt useful in analyses of change? An example with education and cognitive change. Am J Epidemiol. 2005;162:267–78.
   PubMed Web of Science ®Google Scholar
• Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, McGrath M, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(Suppl 1):19–32.
   PubMed Web of Science ®Google Scholar
• D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509–27.
   PubMed Web of Science ®Google Scholar
• Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–62.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience. 2014;274:242–9.
   PubMed Web of Science ®Google Scholar
• Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia. 2007;55:463–72.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PloS One. 2012;7:e37331.
   PubMed Web of Science ®Google Scholar
• Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci USA. 2013;110:300–5.
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson's disease: a randomized clinical trial. JAMA Neurology. 2014;71:141–50.
   PubMed Web of Science ®Google Scholar
• Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol. 2016;67:407–16.
   PubMed Web of Science ®Google Scholar